Clinical outcome and bromodeoxyuridine derived proliferation indices in 75 invasive breast carcinomas
Clinical outcome and bromodeoxyuridine derived proliferation indices in 75 invasive breast carcinomas
INTRODUCTION: In vivo labelling of human breast tumours with bromodeoxyuridine (BrdUrd) and analysis by flow cytometry (FCM) allows the labelling index (LI), S phase duration (t(s)) and the potential doubling time (t(pot)) of the tumour to be estimated.
METHODS: The data for a series of tumour specimens from 75 patients with invasive breast carcinoma were reported in 1991, correlated with their lymph-node status, tumour size and grade.
RESULTS AND CONCLUSIONS: This study reports the follow-up data over 10 years in respect of time to recurrence and death from the disease. There were no significant correlations between proliferation data and outcome measures. No adverse events were identified which could be attributed to the use of the halogenated pyrimidine label in vivo.
breast cancer, bromodeoxyuridine, recurrence, outcome
747-750
Cutress, R. I.
68ae4f86-e8cf-411f-a335-cdba51797406
Mullee, M. A.
243e4a43-2dd4-463d-8b88-c2b5d4bfe608
Royle, G. T.
1fdbdd22-5cfe-4b4b-815a-12a229debe36
Rew, D. A.
36dcc3ad-2379-4b61-a468-5c623d796887
December 2000
Cutress, R. I.
68ae4f86-e8cf-411f-a335-cdba51797406
Mullee, M. A.
243e4a43-2dd4-463d-8b88-c2b5d4bfe608
Royle, G. T.
1fdbdd22-5cfe-4b4b-815a-12a229debe36
Rew, D. A.
36dcc3ad-2379-4b61-a468-5c623d796887
Cutress, R. I., Mullee, M. A., Royle, G. T. and Rew, D. A.
(2000)
Clinical outcome and bromodeoxyuridine derived proliferation indices in 75 invasive breast carcinomas.
European Journal of Surgical Oncology, 26 (8), .
(doi:10.1053/ejso.2000.0997).
(PMID:11087639)
Abstract
INTRODUCTION: In vivo labelling of human breast tumours with bromodeoxyuridine (BrdUrd) and analysis by flow cytometry (FCM) allows the labelling index (LI), S phase duration (t(s)) and the potential doubling time (t(pot)) of the tumour to be estimated.
METHODS: The data for a series of tumour specimens from 75 patients with invasive breast carcinoma were reported in 1991, correlated with their lymph-node status, tumour size and grade.
RESULTS AND CONCLUSIONS: This study reports the follow-up data over 10 years in respect of time to recurrence and death from the disease. There were no significant correlations between proliferation data and outcome measures. No adverse events were identified which could be attributed to the use of the halogenated pyrimidine label in vivo.
This record has no associated files available for download.
More information
Published date: December 2000
Keywords:
breast cancer, bromodeoxyuridine, recurrence, outcome
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 352085
URI: http://eprints.soton.ac.uk/id/eprint/352085
ISSN: 0748-7983
PURE UUID: 9ac20a8f-6591-4e25-ae23-e2f98e9c1127
Catalogue record
Date deposited: 01 May 2013 11:51
Last modified: 15 Mar 2024 04:05
Export record
Altmetrics
Contributors
Author:
M. A. Mullee
Author:
G. T. Royle
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
